Current
19.9×
5-Year Average
18.7×
All-Time High
160.1×
All-Time Low
6.9×
P/E Ratio daily chart for Pfizer (PFE)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/E ratio is not shown for periods when TTM earnings were negative.
Historical P/E Ratio for Pfizer (PFE) from 2001 to 2025
| 2025 | $141.50B | $7.77B | 18.2× | -0.5× | |
| 2024 | $150.35B | $8.02B | 18.7× | -57.4× | |
| 2023 | $162.58B | $2.13B | 76.2× | +67.0× | |
| 2022 | $287.71B | $31.37B | 9.2× | -5.7× | |
| 2021 | $331.62B | $22.23B | 14.9× | -7.4× | |
| 2020 | $204.74B | $9.16B | 22.4× | +9.7× | |
| 2019 | $205.57B | $16.27B | 12.6× | -8.8× | |
| 2018 | $239.51B | $11.15B | 21.5× | +11.9× | |
| 2017 | $204.71B | $21.31B | 9.6× | -16.4× | |
| 2016 | $186.90B | $7.18B | 26.0× | -1.1× | |
| 2015 | $188.92B | $6.96B | 27.1× | +6.8× | |
| 2014 | $185.92B | $9.13B | 20.4× | +11.9× | |
| 2013 | $187.10B | $22.01B | 8.5× | -3.4× | |
| 2012 | $173.97B | $14.57B | 11.9× | -3.7× | |
| 2011 | $156.59B | $10.01B | 15.6× | -0.5× | |
| 2010 | $132.95B | $8.26B | 16.1× | +2.6× | |
| 2009 | $116.58B | $8.63B | 13.5× | -0.4× | |
| 2008 | $112.80B | $8.10B | 13.9× | -4.0× | |
| 2007 | $146.02B | $8.14B | 17.9× | +8.9× | |
| 2006 | $175.36B | $19.33B | 9.1× | -11.0× | |
| 2005 | $162.02B | $8.08B | 20.0× | +3.3× | |
| 2004 | $190.21B | $11.36B | 16.7× | -48.3× | |
| 2003 | $254.07B | $3.91B | 65.0× | +45.6× | |
| 2002 | $176.98B | $9.13B | 19.4× | -10.8× | |
| 2001 | $234.90B | $7.79B | 30.2× | — |
- 202518.2×
- 202418.7×
- 202376.2×
- 20229.2×
- 202114.9×
- 202022.4×
- 201912.6×
- 201821.5×
- 20179.6×
- 201626.0×
- 201527.1×
- 201420.4×
- 20138.5×
- 201211.9×
- 201115.6×
- 201016.1×
- 200913.5×
- 200813.9×
- 200717.9×
- 20069.1×
- 200520.0×
- 200416.7×
- 200365.0×
- 200219.4×
- 200130.2×
About P/E Ratio at Pfizer (PFE)
Pfizer (PFE) P/E ratio is 19.9× as of June 5, 2026. The 5-year average is 18.7×. The sector median currently stands at 25.0×. The current ratio is at the 80th percentile of its own 10-year history.
Pfizer (PFE) historical P/E ratio has ranged from a low of 6.9× (2023) to a high of 160.1× (2004) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Pfizer P/E Ratio by Year
Pfizer P/E Ratio 2025: 18.2×
Pfizer (PFE) P/E ratio in 2025 was 18.2×, contracted from 18.7× the prior year.
Pfizer P/E Ratio 2024: 18.7×
Pfizer (PFE) P/E ratio in 2024 was 18.7×, contracted from 76.2× the prior year.
Pfizer P/E Ratio 2023: 76.2×
Pfizer (PFE) P/E ratio in 2023 was 76.2×, expanded from 9.2× the prior year.
Pfizer P/E Ratio 2022: 9.2×
Pfizer (PFE) P/E ratio in 2022 was 9.2×, contracted from 14.9× the prior year.
Pfizer P/E Ratio 2021: 14.9×
Pfizer (PFE) P/E ratio in 2021 was 14.9×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Pfizer (PFE), ranked by P/E ratio.
| 23.1× | |
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric